Table 2 Taxane-platinum (TP) versus platinum-based therapy (PC/PAC) in the TP53-negative and TP53-positive group. Interactions between the therapies and clinicopathological factors (multivariate models: the logistic regression and Cox proportional hazards model)*

Complete remission (CR)

PC/PAC

-

1.0

TP

-

>0.1

3.28 [1.22,8.83]

0.018

endometrioid, CCC treated with PC/PAC

1.0

-

endometrioid, CCC treated with TP

>10 [0.92, +]

0.058

-

Platinum sensitivity (PS)

PC/PAC

-

1.0

TP

-

>0.1

1.96 [1.14, 3.35]

0.014

Platinum high sensitivity (PHS)

PC/PAC

1.0

1.0

TP

0.006 [0.001, 0.29]

0.010

10.73 [1.14, +]

0.038

endometrioid, CCC treated with PC/PAC

1.0

-

endometrioid, CCC treated with TP

18.37 [1.25, +]

0.033

-

FIGO IIIA/B treated with PC/PAC

1.0

-

FIGO IIIA/B treated with TP

161 [3.08, +]

0.012

-

FIGO IIIC treated with PC/PAC

1.0

-

FIGO IIIC treated with TP

133 [2.94, +]

0.012

-

Residual tumor >2 cm treated with PC/PAC

-

1.0

Residual tumor >2 cm treated with TP

-

5.95 [1.16, +]

0.032

Grade 3 tumors treated with PC/PAC

-

1.0

Grade 3 tumors treated with TP

-

0.11 [0.01, 1.14]

0.065

Grade 4 tumors treated with PC/PAC

-

1.0

Grade 4 tumors treated with TP

-

0.04 [0.003, 0.55]

0.016

Disease free survival (DFS)

PC/PAC versus TP

>0.1

>0.1

Overall survival (OS, risk of death)

PC/PAC

-

1.0

TP

-

>0.1

0.15 [0.04, 0.60]

0.007

Age >53 treated with PC/PAC

1.0

1.0

Age >53 treated with TP

0.51 [0.24, 1.08]

0.077

0.58 [0.32, 1.07]

0.080

Grade 3 tumors treated with PC/PAC

-

1.0

Grade 3 tumors treated with TP

-

5.76 [1.44, 23.0]

0.013

Grade 4 tumors treated with PC/PAC

-

1.0

Grade 4 tumors treated with TP

-

6.0 [1.43, 25.5]

0.015